Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus
This study evaluates the immune response for patients affected by metastatic breast cancer treated by everolimus
Breast Cancer
OTHER: additional blood sample
level of the spontaneous anti-telomerase response, evaluation by Enzyme-Linked Immunospot (ELIspot) and by Enzyme-Linked Immunosorbent Assay (ELISA test), 12 months
T lymphocytes level, 12 months|everolimus level in serum patients, 12 months|angiopoietin 2 level, 12 months|CD138 level, 12 months|ps6K expression, 12 months|Merlin expression, 12 months|neuropilin 2 expression, 12 months|quality of life, EUROQOL EQ-5D, EORTC QLQ-C30 and BR 23, 12 months
This study evaluates the immune response for patients affected by metastatic breast cancer treated by everolimus